Tomoo Osumi
Overview
Explore the profile of Tomoo Osumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toyosaki M, Doki N, Shiratori S, Osumi T, Okada M, Kawakita T, et al.
Blood Cell Ther
. 2023 Dec;
6(4):104-113.
PMID: 38149026
Background: Chronic graft-versus-host disease (cGVHD) is a serious complication after allogeneic stem cell transplantation. Poor prognosis has been shown in patients with cGVHD after the failure of primary steroid-based treatments....
2.
Mori T, Osumi T, Kada A, Ohki K, Koga Y, Fukano R, et al.
Eur J Haematol
. 2023 Dec;
112(4):585-593.
PMID: 38112205
Background: The benefit of adding rituximab to standard lymphomes malins B (LMB) chemotherapy for children with high-risk mature B-cell non-Hodgkin lymphoma (B-NHL) has previously been demonstrated in an international randomized...
3.
Yoshida M, Nakabayashi K, Yang W, Sato-Otsubo A, Tsujimoto S, Ogata-Kawata H, et al.
Cancer Med
. 2023 Apr;
12(10):11264-11273.
PMID: 37021926
Background: Second malignant neoplasms (SMNs) are one of the most severe late complications after pediatric cancer treatment. However, the effect of genetic variation on SMNs remains unclear. In this study,...
4.
Shirai R, Osumi T, Keino D, Nakabayashi K, Uchiyama T, Sekiguchi M, et al.
Int J Hematol
. 2023 Mar;
117(6):910-918.
PMID: 36867356
Minimal residual disease (MRD) is usually defined as the small number of cancer cells that remain in the body after treatment. The clinical significance of MRD kinetics is well recognized...
5.
Hori D, Kobayashi R, Nakazawa A, Iwafuchi H, Klapper W, Osumi T, et al.
Pediatr Blood Cancer
. 2023 Mar;
70(5):e30279.
PMID: 36860130
Background: Diffuse large B-cell lymphoma (DLBCL) is classified into two molecular subtypes according to its cell of origin: germinal center B-cell (GCB) subtype and activated B-cell/non-GCB subtype. This latter subtype...
6.
Matsukawa Y, Isshiki K, Osumi T, Fujiyama S, Fukushima H, Uchiyama T, et al.
Blood Cell Ther
. 2023 Jan;
5(3):75-78.
PMID: 36712554
Omenn syndrome (OS) is typically observed in the autosomal recessive form of severe combined immunodeficiency (SCID) with autoreactive manifestations, and it requires allogeneic hematopoietic stem cell transplantation. Unlike non-OS SCID,...
7.
Tsujimoto S, Sakamoto K, Nakano Y, Mizuno T, Shindo T, Watanabe J, et al.
Pediatr Blood Cancer
. 2022 Oct;
70(3):e30033.
PMID: 36184828
No abstract available.
8.
Yoshida M, Brown S, Moriyama T, Nishii R, Tsujimoto S, Yamada Y, et al.
Br J Haematol
. 2022 Jul;
199(2):270-276.
PMID: 35905175
6-Mercaptopurine (6-MP) is widely used for the treatment of paediatric leukaemia and lymphoma. Recently, germline variants in the NUDT15 gene have been identified as one of the major genetic causes...
9.
Shirai R, Osumi T, Sato-Otsubo A, Nakabayashi K, Ishiwata K, Yamada Y, et al.
Genes Chromosomes Cancer
. 2022 Jun;
61(11):662-669.
PMID: 35655408
Liquid biopsy, a method of detecting genomic alterations using blood specimens, has recently attracted attention as a noninvasive alternative to surgical tissue biopsy. We attempted quantitative analysis to detect amplification...
10.
Yamada Y, Osumi T, Kato M, Shioda Y, Kiyotani C, Terashima K, et al.
J Pediatr Hematol Oncol
. 2022 Jan;
44(4):178-180.
PMID: 35091516
There is no established treatment for patients with acute promyelocytic leukemia (APL) refractory to targeted therapies with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). We report here a case...